CORMEDIX INC (CRMD)
Health Care · NASDAQ
CorMedix commercializes antimicrobial catheter lock solutions and acquired infectious disease products to prevent catheter-related bloodstream infections in hospital and dialysis settings.
What CORMEDIX INC does
CorMedix is a biopharmaceutical company focused on commercializing therapeutic products for life-threatening infectious diseases and conditions. The company's flagship product is DefenCath (taurolidine and heparin), an antimicrobial catheter lock solution launched in 2024 to reduce catheter-related bloodstream infections in hemodialysis patients. In August 2025, CorMedix acquired Melinta Therapeutics, expanding its portfolio with six marketed infectious disease products (including REZZAYO, MINOCIN IV, VABOMERE, KIMYRSA, ORBACTIV, BAXDELA) and a cardiovascular product (TOPROL-XL), enabling a multi-channel commercial strategy across hospitals, emergency departments, and outpatient clinics.
Themes: ["Catheter-related bloodstream infection (CRBSI) prevention"]
Fundamentals
- Price$8.67 as of 2026-07-09 close
- Market cap$693M as of 2026-07-10
- 1-year return-23.6% as of 2026-07-09 close
- P/E3.83 as of 2026-07-10
- Net margin+45.3% as of 2026-07-10
- Gross margin+85.8% as of 2026-07-10
- ROE+50.4% as of 2026-07-10
- Debt / equity0.33 as of 2026-07-10
- Revenue growth (YoY)+384.6% as of 2026-07-10
- Revenue CAGR (3y)+535.6% SEC XBRL
- Beta1.51 as of 2026-07-10
Key risks (from latest filing)
["DefenCath is a newly launched product with limited commercial history; customer adoption and market penetration in the highly competitive hemodialysis setting remain uncertain."]
Competitors & peers
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.